• Policy / Pricing

German said to be backtracking on pharma rebate changes

pharminent June 16, 2026

• Regulatory

FDA and MHRA forge new regulatory collaboration initiative

pharminent June 16, 2026

• News

pharminent June 15, 2026

• News

pharminent June 15, 2026

• Manufacturing

Eisai claims UK grant to expand manufacturing site

pharminent June 15, 2026

• Clinical Data

Key pipeline drug for Lundbeck delivers in Cushing syndrome

pharminent June 15, 2026

• Clinical Data

Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease

pharminent June 15, 2026

• Clinical Data

Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacy

pharminent June 15, 2026

• Clinical Data

Data could move J&J’s Talvey earlier in myeloma therapy

pharminent June 15, 2026

• Regulatory

FDA clears MSD’s Keytruda combo plus Welireg for ccRCC treatment

pharminent June 15, 2026

• News

pharminent June 12, 2026

• Market Access

pharminent June 12, 2026

• Manufacturing

FDA imposes import alert on Indian plant after inspectors flag GMP failings

pharminent June 12, 2026

• Clinical Data

Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win

pharminent June 12, 2026

• Regulatory

Novo Nordisk comeback stirs as Wegovy pill wins UK approval

pharminent June 12, 2026

• Regulatory

China’s NMPA approves Akeso’s gumokimab for plaque psoriasis

pharminent June 12, 2026

• News

pharminent June 11, 2026

• Policy / Pricing

How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan Market

pharminent June 11, 2026

• Policy / Pricing

Medicare Part D Enrollment, Premiums, and Cost Sharing in 2026

pharminent June 11, 2026

• M&A / Deals

Sky-high Parabilis, Kailera IPOs spur optimism–but only for derisked biotechs

pharminent June 11, 2026

• Pipeline

J&J adds rare disease wAIHA to Imaavy’s potential uses

pharminent June 11, 2026

• Pipeline

Novartis gets win for another Avidity muscular dystrophy AOC

pharminent June 11, 2026

• M&A / Deals

SonoThera bags $125M series B to advance safer gene therapies

pharminent June 11, 2026

• Clinical Data

Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test

pharminent June 11, 2026

• M&A / Deals

Beren pockets $300m to take Niemann-Pick disease therapy to market

pharminent June 11, 2026

• Market Access

Aquipta recommended by NICE for acute migraine treatment

pharminent June 10, 2026

• Regulatory

Lilly wins new FDA approval for eczema drug Ebglyss

pharminent June 10, 2026

• Regulatory

Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug

pharminent June 10, 2026

• Regulatory

Bayer’s asundexian starts EU review for ischaemic stroke

pharminent June 10, 2026

• Market Access

AbbVie’s migraine drug cleared for migraine attacks on NHS

pharminent June 10, 2026

• M&A / Deals

Aditxt and Ignite announce merger plans with strategic partner

pharminent June 10, 2026

• M&A / Deals

Cancer biotech Parabilis books record IPO, raising $670m

pharminent June 10, 2026

• M&A / Deals

Alzecure enters collaboration and with Lilly for Alzheimer’s project

pharminent June 9, 2026

• Clinical Data

ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data

pharminent June 9, 2026

• M&A / Deals

GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year

pharminent June 9, 2026

• Regulatory

ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval

pharminent June 9, 2026

• Clinical Data

ADA: AZ reveals oral GLP-1 data in obesity, diabetes

pharminent June 9, 2026

• Regulatory

Pfizer’s Hympavzi secures FDA expanded indications for haemophilia

pharminent June 9, 2026

• M&A / Deals

J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B

pharminent June 8, 2026

• Commercial

ADA ’26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option

pharminent June 8, 2026